Testing version — LOERadar is in active testing. Features and data may change.

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE) | LOERadar

Viewing data from:

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

ANDA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE | A205401 | ANI PHARMACEUTICALS INC

6 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ADDERALL XR 10(TE code: AB1)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
SHIRE LLC v. AMERIGEN PHARMACEUTICALS LIMITED 1:2014cv06095 4 patentsANDA 205401dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	D.N.J.	2014-10-01	Terminated 2017-03-02	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Products (6)

Sort:

#001 — 1.25MG;1.25MG;1.25MG;1.25MG

AB1

0 patents0 exclusivities▴

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jan 22, 2019

No patent or exclusivity listings for this strength.

#002 — 2.5MG;2.5MG;2.5MG;2.5MG

AB1

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jan 22, 2019

#003 — 3.75MG;3.75MG;3.75MG;3.75MG

AB1

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jan 22, 2019

#004 — 5MG;5MG;5MG;5MG

AB1

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jan 22, 2019

#005 — 6.25MG;6.25MG;6.25MG;6.25MG

AB1

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jan 22, 2019

#006 — 7.5MG;7.5MG;7.5MG;7.5MG

AB1

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jan 22, 2019